Embassy OF THE United States OF AME Pharmaceutical Import Profile — Tanzania (DGFT 2022–2026)

Name: Embassy OF THE United States OF AME Pharmaceutical Import Records from India — 3 Products, $450.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Embassy OF THE United States OF AME — Pharmaceutical Importer Profile (2026) | 3 Products, $450.0K Trade | TransData Nexus

Embassy OF THE United States OF AME

Pharmaceutical Importer · Tanzania · Antiviral & HIV Medications Focus · $450.0K Total Trade · DGFT Verified

Embassy OF THE United States OF AME is a pharmaceutical importer based in Tanzania with a total trade value of $450.0K across 3 products in 1 therapeutic categories. Based on 9 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Embassy OF THE United States OF AME sources from 1 verified Indian supplier, with Mylan Laboratories Limited accounting for 100.0% of imports.

Embassy OF THE United States OF AME — Import Portfolio & Supplier Network

Embassy OF THE United States OF AME import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Embassy OF THE United States OF AME?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$861.2K	19	100.0%

Embassy OF THE United States OF AME sources from 1 verified Indian supplier across 8 distinct formulations. The sourcing is highly concentrated — Mylan Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Tenofovir disoproxil fumarate 300 MG+	$263.7K	6
Atazanavir 300MG + ritonavir 100MG)	$150.0K	3
Tenofovir disoproxil fumarate 300 MG+emtricitabine 200 MG TAB(30's) (322731 packs x 30's = 9681930 nos	$150.0K	3
Tenofovir disoproxil fumarate 300	$100.0K	2
Tenofovir disoproxil fumarate 300 MG+ emtricitabine 200 MG tab30's 131985 packs x 30's =3959550	$50.0K	1
Tenofovir disoproxil fumarate 300 MG+emtricitabine 200 MG tab30's 64586 packs x 30's =1937580	$50.0K	1
Tenofovir disoproxil fumarate 300 MG+ emtricitabine 200 MG tab30's 54675 packs x 30's=1640250	$50.0K	1
Lamivudine 30MG + zidovudine 60MG	$47.5K	2

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Atazanavir	Antiviral & HIV Medications	$150.0K	3	0.2%	2
2	Emtricitabine	Antiviral & HIV Medications	$150.0K	3	0.1%	15
3	Ritonavir	Antiviral & HIV Medications	$150.0K	3	0.0%	10

Embassy OF THE United States OF AME imports 3 pharmaceutical products across 1 categories into Tanzania totaling $450.0K.

Embassy OF THE United States OF AME — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The Embassy of the United States of America in Tanzania is the diplomatic mission representing the U.S. government in the country. As a government entity, it is not a commercial pharmaceutical buyer or importer. Therefore, it does not engage in the importation or distribution of pharmaceutical products. The data indicating the Embassy as a pharmaceutical importer is likely a misclassification or error in the trade records.

2Distribution Network

As a diplomatic mission, the Embassy does not operate a distribution network for pharmaceutical products. Its logistical operations are focused on diplomatic functions and do not extend to the importation or distribution of medical supplies.

3Industry Role

The Embassy does not participate in Tanzania's pharmaceutical supply chain. Its role is strictly diplomatic, and it does not function as a wholesaler, parallel importer, hospital supplier, or logistics intermediary in the pharmaceutical sector.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Embassy OF THE United States OF AME

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Given that the Embassy does not import pharmaceutical products, there is no supplier concentration to analyze. The data suggesting such activity is erroneous and does not reflect the Embassy's operations.

2Supply Chain Resilience

The Embassy does not have a pharmaceutical supply chain, and therefore, considerations regarding its resilience, backup suppliers, formulation diversity, shipping route exposure, or regulatory compliance of suppliers are not applicable.

3Strategic Implications

Since the Embassy does not engage in pharmaceutical sourcing, there are no strategic implications regarding its competitive position or for Indian exporters seeking to become alternative suppliers.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Tanzania — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Tanzania

1Regulatory Authority & Framework

The Tanzania Medicines and Medical Devices Authority (TMDA) is the primary regulatory body overseeing the importation and exportation of pharmaceutical products in Tanzania. The Pharmaceutical and Poisons Act, along with its regulations, governs these activities, ensuring that all pharmaceutical products imported into the country are registered and meet the required standards. The registration process involves submitting an application to the TMDA, accompanied by necessary documentation and fees. The Act also outlines the control of manufacture, sale, supply, import, and export of pharmaceutical products, emphasizing the need for appropriate licenses issued by the Board.

2Import Licensing & GMP

Importers of pharmaceutical products in Tanzania must obtain an import license from the TMDA. This license is specific to each consignment and is not transferable. The application process requires submission of a proforma invoice, certificate of analysis, and other relevant documents. Regarding Good Manufacturing Practice (GMP), the TMDA recognizes certifications from reputable bodies such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certificates from these recognized organizations. (tmda.go.tz)

Embassy OF THE United States OF AME — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

The data indicating the Embassy's importation of antiviral and HIV medications is incorrect. As a diplomatic mission, the Embassy does not engage in the importation of pharmaceutical products. Therefore, there is no product category focus or market demand driving such imports.

2Sourcing Profile

The Embassy does not have a pharmaceutical sourcing strategy, as it does not import pharmaceutical products. Consequently, there are no formulation preferences or procurement considerations to analyze.

3Market Positioning

Given that the Embassy does not participate in the pharmaceutical market, it does not serve any segment of the Tanzania market, such as retail pharmacy, hospital, government tenders, or wholesale distribution.

TransData Nexus Research · DGFT trade data analysisMar 2026

Seller's Guide — How to Become a Supplier to Embassy OF THE United States OF AME

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is no opportunity for new Indian suppliers to engage with the Embassy in the pharmaceutical sector, as the Embassy does not import pharmaceutical products. The data suggesting such activity is erroneous and does not reflect the Embassy's operations.

2Requirements & Qualifications

Since the Embassy does not import pharmaceutical products, there are no certifications, quality standards, or regulatory approvals required for Indian exporters to supply to the Embassy.

3How to Approach

As the Embassy does not engage in pharmaceutical importation, there are no practical steps for building a relationship, participating in tenders, or developing a regulatory filing strategy with the Embassy in this sector.

TransData Nexus Research · Industry procurement practices

Frequently Asked Questions — Embassy OF THE United States OF AME

What products does Embassy OF THE United States OF AME import from India?

Embassy OF THE United States OF AME imports 3 pharmaceutical products across 1 categories. Top imports: Atazanavir ($150.0K), Emtricitabine ($150.0K), Ritonavir ($150.0K).

Who supplies pharmaceuticals to Embassy OF THE United States OF AME from India?

Embassy OF THE United States OF AME sources from 1 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (100.0% of imports, $861.2K).

What is Embassy OF THE United States OF AME's total pharmaceutical import value?

Embassy OF THE United States OF AME's total pharmaceutical import value from India is $450.0K, based on 9 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Embassy OF THE United States OF AME focus on?

Embassy OF THE United States OF AME imports across 1 categories. The largest: Antiviral & HIV Medications (100.0%).

Get Full Embassy OF THE United States OF AME Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.